FDA approves quarterly siRNA for myasthenia gravis
MDSpire News
November 19, 2026
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

The FDA approved cemdisiran, the first siRNA therapy for adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis.
Cemdisiran targets messenger RNA encoding complement component 5 and is administered subcutaneously at 567 mg every 3 months by a health care provider.
In the phase 3 NIMBLE trial, cemdisiran improved MG-ADL scores by 4.5 points at week 24, compared with 2.2 points with placebo.
Cemdisiran improved QMG scores by 4.2 points at week 24, compared with 1.5 points with placebo.
Cemdisiran carries a boxed warning for serious meningococcal infections and is available only through a restricted Risk Evaluation and Mitigation Strategy program.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: